IL17A and autoimmune disease: One limitation is the use of PBMCs from healthy adults, which have a lower absolute quantity of autoimmune disease-specific T cells and cytokines, such as Tfh cells, IL-17, and IL-21, compared to PBMCs from adults with an autoimmune disease.